Top of this page
Skip navigation, go straight to the content Newsroom UCB U.S. News


  • Case Study: The Right Patients at the Right Time

    Posted by Katelyn Snider, U.S. Communications and Public Affairs

    Following a recent review of Tussionex® (hydrocodone polistirex and chlorpheniramine polistirex) – a cough syrup containing hydrocodone and chlorpheniramine– we determined the benefit-risk balance for the use of Tussionex® to treat cough associated with cold or allergy in children was no longer favorable. Because of this, UCB proactively approached the U.S. Food and Drug Administration (FDA) to request that Tussionex® be limited to use in adults.

    Read more

  • Like